| ‘Cytokine defined’B cell subsets in multiple sclerosis R Li, S Fillatreau, J Gommerman, A Prat, A Bar-or Journal of Neuroimmunology 275 (1), 10, 2014 | | 2014 |
| " A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis": Correction. JM Burton, S Kimball, R Vieth, A Bar-Or, HM Dosch, R Cheung, D Gagne, ... Lippincott Williams & Wilkins, 2010 | | 2010 |
| “Ependymal‐in” gradient of thalamic damage in progressive multiple sclerosis R Magliozzi, G Fadda, RA Brown, A Bar‐Or, OW Howell, S Hametner, ... Annals of Neurology 92 (4), 670-685, 2022 | 26 | 2022 |
| (DMT03) Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials. AH Cross, L Kappos, A Bar-Or, JA Cohen, G Comi, J Correale, PK Coyle, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT02) Early Effect of Ofatumumab on B-Cell Counts and Magnetic Resonance Imaging Activity in Relapsing Multiple Sclerosis Patients: Results from the APLIOS Study. A Bar-Or, EJ Fox, A Goodyear, I Ludwig, M Bagger, DA Haering, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT03) Analyses of the Effect of Disease Duration on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the EXPAND Study. A Bar-Or, SL Cohan, PK Coyle, FD Lublin, X Meng, W Su, BAC Cree International Journal of MS Care 22, 2020 | | 2020 |
| (DXT04) Siponimod First-Dose Effects in Patients with Secondary Progressive Multiple Sclerosis Receiving Concomitant Selective Serotonin Reuptake Inhibitor Therapy. A Bar-Or, BAC Cree, LH Hua, A Katz, D Robertson, B Brown, D Dunlop, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT10) Siponimod Affects Disability Progression in Patients with Secondary Progressive Multiple Sclerosis Independent of Relapse Activity: Results from the Phase 3 EXPAND Study. BAC Cree, RJ Fox, G Giovannoni, P Vermersch, A Bar-Or, R Gold, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT43) Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the EXPAND Study. LH Hua, A Bar-Or, FD Lublin, X Meng, W Su, BAC Cree, RJ Fox International Journal of MS Care 22, 2020 | | 2020 |
| (DXT60) Correlations Between Four Common Measures of Cognition in Patients with Secondary Progressive Multiple Sclerosis. RHB Benedict, X Meng, A Bar-Or, BAC Cree, RJ Fox, P Vermersch, W Su, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT61) Injection-Related Reactions with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Pooled Analysis of the Phase 3 ASCLEPIOS I and II Trials. R Pingili, A Bar-Or, JA Cohen, PK Coyle, AH Cross, SL Hauser, L Kappos, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT78) The FLUENT Study: Changes in Immune Cell Profile, and in Clinical and Safety Outcomes, in Fingolimod-Treated Patients with Relapsing Multiple Sclerosis. Y Mao-Draayer, JA Cohen, A Bar-Or, MH Han, BA Singer, N Jaitly, ... International Journal of MS Care 22, 2020 | | 2020 |
| 010 Safety and efficacy of long-term dimethyl fumarate treatment R Gold, G Giovannoni, JT Phillips, A Bar-Or, RJ Fox, C Chen, B Parks, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (6), A16-A17, 2022 | | 2022 |
| 033 Ocrelizumab: serum Ig levels and serious infections K Schmierer, A Bar-Or, R Bermel, MS Weber, R Hughes, CJ Lin, J Wang, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (6), A23-A24, 2022 | | 2022 |
| 043 Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis R Gold, L Kappos, A Bar-Or, P Vermersch, G Giovannoni, RJ Fox, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (6), A27-A27, 2022 | | 2022 |
| 045 Effect of siponimod on cortical grey matter and thalamic volume in secondary progressive multiple sclerosis DL Arnold, RJ Fox, A Bar-Or, BAC Cree, G Giovannoni, R Gold, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (6), A27-A27, 2022 | | 2022 |
| 115 Impact of siponimod on myelination across SPMS subgroups: post-hoc analysis from EXPAND MRI substudy DL Arnold, A Bar-Or, BAC Cree, G Giovannoni, R Gold, P Vermersch, ... Journal of Neurology, Neurosurgery and Psychiatry 93 (6), A137-A137, 2022 | 1 | 2022 |
| 116 Serum immunoglobulin levels and infection risk in Phase 3 ofatumumab trials in relapsing multiple sclerosis H Wiendl, J de Seze, A Bar-Or, J Correale, A Cross, L Kappos, K Selmaj, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (6), A137-A137, 2022 | | 2022 |
| 118 Sustained reduction of disability and cognitive decline with long-term siponimod in EXPAND active SPMS patients G Giovannoni, L Kappos, RJ Fox, P Vermersch, BAC Cree, RHB Benedict, ... Journal of Neurology, Neurosurgery and Psychiatry 93 (6), A138-A138, 2022 | | 2022 |
| 12-Year Clinical Efficacy and Safety Data for Teriflunomide: Results from a Phase 2 Extension Study (P7. 223) M Kremenchutzky, M Freedman, A Bar-Or, D Dukovic, M Benamor, ... Neurology 84 (14_supplement), P7. 223, 2015 | 4 | 2015 |
Ludwig KapposUniversity Hospital Basel在 uhbs.ch 的电子邮件经过验证
